Rezivertinib
- Generic Name
- Rezivertinib
- Indication
用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的治疗。
Rezivertinib Shows Superior Efficacy Over Gefitinib in EGFR-Mutated NSCLC Phase III Trial
• Rezivertinib demonstrated significantly longer progression-free survival (19.3 months vs 9.6 months) compared to gefitinib in patients with EGFR-mutated non-small cell lung cancer in the Phase III REZOR trial.
• The novel therapy maintained a comparable safety profile to gefitinib, with similar rates of grade 3 or higher treatment-related adverse events (23%) in both treatment groups.
• Patients with CNS metastases showed marked improvement with rezivertinib (16.0 months PFS vs 9.7 months), offering a promising new first-line treatment option for advanced NSCLC patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath